The aim of this study was to evaluate the efficacy and safety of Sofosbuvir/Ledipasvir ± Ribavirin in Malagasy patients with hepatitis C virus genotypes 1 and 2 in real conditions.
This was a retro-prospective, monocentric clinical study, carried out over a period of 3 years from March 1, 2017 to February 28, 2020, in Hepato-gastroenterology department.
A total of 26 patients (M/F: 11/15) with hepatitis C virus genotype 1 (n = 13) and genotype 2 (n = 13), were treated with Sofosbuvir/Ledipasvir without (n = 21) and with (n = 5) Ribavirin for 12 weeks. The mean age was 61.38 ± 7.09. Seventeen (65.4%) patients had cirrhosis. The overall sustained virological response was 96.2% (95% CI = 80.4-99.9%). There was no significant difference between the sustained virological response of genotypes 1 and 2 (92.3% vs. 100%; p = 0.31) and cirrhotic or non-cirrhotic patients (94.1% vs. 100%; p = 0.46). A relapse was observed in one patient (5.9%), cirrhotic, genotype 1b, under Sofosbuvir/Ledipasvir with Ribavirin. Seven patients (26.9%) experienced mild adverse reactions including asthenia (57.1%) and insomnia (42.9%).
Treatment with Sofosbuvir/Ledipasvir ± Ribavirin for infection with hepatitis C virus genotypes 1 has been shown to be safe and effective, even in the presence of cirrhosis. The combination Sofosbuvir/Ledipasvir is a good option for genotype 2 non-cirrhotic patients.
Copyright © 2021. Published by Elsevier Ltd.
About The Expert
Chantelli Iamblaudiot Razafindrazoto
Anjaramalala Sitraka Rasolonjatovo
Tovo Harimanana Rabenjanahary
Nitah Harivony Randriamifidy
Andry Lalaina Rinà Rakotozafindrabe
Soloniaina Hélio Razafimahefa
Rado Manitrala Ramanampamonjy
References
PubMed